Karyopharm Therapeutics Inc. (KPTI)

1,1500 +0,0200 (+1,77 %) À la clôture : 04:00PM EDT

Karyopharm Therapeutics Inc.

85 Wells Avenue
Suite 210
Newton, MA 02459-3298
United States
617 658 0600
https://www.karyopharm.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 325

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Richard A. Paulson M.B.A.	President, CEO & Director	1,43M	S.O.	1967
Mr. Michael P. Mason CPA, M.B.A.	Executive VP, CFO & Treasurer	712,68k	S.O.	1975
Ms. Sohanya Cheng M.B.A.	Executive VP & Chief Commercial Officer	742,95k	S.O.	1983
Mr. Stuart Poulton	Executive VP & Chief Development Officer	682,48k	S.O.	S.O.
Dr. Reshma Rangwala M.D., Ph.D.	Executive VP, Chief Medical Officer & Head of Research	777,32k	S.O.	1978
Dr. Mansoor Raza Mirza M.D.	Clinical Consultant, Member of Scientific Advisory Board & Independent Director	150k	S.O.	1961
Dr. Sharon Shacham M.B.A., Ph.D.	Co-Founder & Chairman of Scientific Advisory Board	1,4M	S.O.	1970
Mr. Cameron Peters	Vice President of Finance, Assistant Treasurer & Principal Accounting Officer	S.O.	S.O.	1960
Ms. Elhan Webb C.F.A.	Senior Vice President of Investor Relations	S.O.	S.O.	S.O.
Mr. Michael J. Mano J.D.	Senior VP, General Counsel & Secretary	625,08k	S.O.	1977

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Karyopharm Therapeutics Inc. en date du 1 mai 2024 est 8. Les scores principaux sont Audit : 8; Société : 8; Droits des actionnaires : 8; Compensation : 7.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.